SI-BONE, Inc.

NASDAQ:SIBN

Medical - Devices

Healthcare
$23.54 +3.45%

+$0.53 today

Market cap
$1.06B
Beta
0.70
P/E (TTM)
-41.4
EPS (TTM)
-$0.38
52W Low $11.48High $21.89

Volume 1.12M

Average 0.68M

SIBN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

SI-BONE, Inc.NASDAQ: SIBN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$2.13M, compared with -$4.6M a year earlier. Trailing-twelve-month EBITDA was -$5.99M.

Context

  • EBITDA amounted to 5.4% of revenue in FY2025, down 8.4 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$5.75M (+47.3%) for the fiscal year ending Dec 2026, a slowdown from the +52.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.13M-179.8% QoQ
Last fiscal yearDec 2025
-$10.91M+52.8% YoY
LTMMar 2026
-$5.99M+68.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.8%-1.2%-55.1 pp
1 year+52.8%+47.3%-5.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(10.91M) USD
Year-over-year change
+52.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SIBN compares with its peers on the latest reported figures

  • SIBN's LTM Mar 2026 EBITDA of -$5.99M is the lowest of the 6 companies compared; the peer median is $945.76M.
  • Its year-over-year change of +68.1% is the 2nd highest of 6, against a peer median of +40.7%.
  • EBITDA amounts to 2.9% of revenue for SIBN, versus a peer median of 21.7%.
SIBN Competitors Peer median
EBITDA for SIBN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$6.69B +40.7%+16.3%25.9%
SNNSmith & Nephew plcFY2025$1.34B +0.1%+5.1%21.7%
GMEDGlobus Medical, Inc.LTM Jun 2026$945.76M +52.8%+42.8%30.1%
CNMDCONMED CorporationLTM Mar 2026$169.63M -31.6%+170.6%12.4%
ATECAlphatec Holdings, Inc.LTM Mar 2026-$1.36M +97.4%—0.2%
SIBNSI-BONE, Inc.LTM Mar 2026-$5.99M +68.1%—2.9%
Peer median (excluding SIBN) $945.76M+40.7%+29.5%21.7%

Competitors are the stored peer set for SIBN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue90.15M106.41M138.89M167.18M200.93M
Cost of Revenue10.43M15.71M29.47M35.06M41.05M
Gross Profit79.72M90.7M109.42M132.12M159.88M
Gross Margin88.4%85.2%78.8%79.0%79.6%
Research & Development12.44M13.63M15.03M16.56M17.45M
Selling, General & Admin118.95M136.69M141.32M150.81M164.76M
Operating Expenses131.39M150.31M156.35M167.37M182.21M
Depreciation & Amortization2.09M3.45M5.43M4.38M2.72M
EBITDA(50.97M)(54.99M)(34.45M)(23.09M)(10.91M)
EBITDA Margin-56.5%-51.7%-24.8%-13.8%-5.4%
Operating Income(51.67M)(59.61M)(46.93M)(35.25M)(22.33M)
Operating Margin-57.3%-56.0%-33.8%-21.1%-11.1%
Interest Income186K1.3M6.92M7.85M6.07M
Interest Expense5.37M2.82M3.46M3.44M5.28M
Other Income / Expenses(4.9M)(1.65M)3.6M4.34M3.42M
Income Before Tax(56.57M)(61.26M)(43.34M)(30.91M)(18.91M)
Pre-Tax Margin-62.8%-57.6%-31.2%-18.5%-9.4%
Income Tax Expense00000
Net Income(56.57M)(61.26M)(43.34M)(30.91M)(18.91M)
Net Margin-62.8%-57.6%-31.2%-18.5%-9.4%
EPS (Basic)(1.71)(1.79)(1.13)(0.75)(0.44)
EPS (Diluted)(1.71)(1.79)(1.13)(0.75)(0.44)
Weighted Avg Shares33.15M34.2M38.43M41.47M43.51M
Weighted Avg Shares (Diluted)33.15M34.2M38.43M41.47M43.51M

SI-BONE, Inc.

NASDAQ:SIBN

Intrinsic Alpha fair value

Locked

Current Price

$23.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.